ABC | Volume 113, Nº3, September 2019

Original Article Figueiredo et al. Rheumatic fever: a disease without color Arq Bras Cardiol. 2019; 113(3):345-354 9. Bland Ef, Duckett Jones T. Rheumatic fever and rheumatic heart disease; a twenty year report on 1000 patients followed since childhood. Circulation. 1951;4(6):836-43. 10. Robertson KA, Volmink JA, Mayosi BM. Antibiotics for the primary prevention of acute rheumatic fever: a meta-analysis. BMC Cardiovasc Disord. 2005;5(1):11. 11. Brasil. Ministério da Saúde. Sistema de Informação Hospitalar do SUS - DATASUS [internet]. 2018. [acesso em10 jan 2018]. Disponível em: http:// datasus.saude.gov.br/. 12. Brasil. Ministério da Saúde. Câncer demama : é preciso falar disso. Instituto Nacional do Câncer José Alencar Gomes da Silva; 2014. 13. Brasil. Ministério da Saúde. Câncer de próstata: Vamos falar sobre isso? Inst Nac do Câncer José Alencar Gomes da Silva; 2017. 14. Brasil. Ministério da Saúde. Sistema de Gerenciamento da Tabela de Procedimentos Medicamentos, OPM do SUS – SIGTAP. 2018. [acesso em 08 fev 2018]. Disponível em: http://sigtap.datasus.gov.br . 15. Brasil.Ministério da Saúde.Agência Nacional de Vigilância Sanitária (ANVISA) Câmara de Regulação do Mercado de Medicamentos – CMED. 2018. [acesso em 08 fev 2018]. Disponível em: http://portal. anvisa.gov.br/cmed. 16. Zühlke L, Engel ME, Karthikeyan G, Rangarajan S, Mackie P, Cupido B, et al. Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: The Global Rheumatic Heart Disease Registry (the REMEDY study). Eur Heart J. 2015;36(18):1115-22a. 17. Andrews DWK, Monahan JC. An improved heteroskedasticity and autocorrelation consistent covariance matrix estimator. Econometrica. 1992;60(4):953-66. 18. HoltCC.Forecastingseasonalsandtrendsbyexponentiallyweightedmoving averages. Int J Forecast. 2004;20(1):5-10. 19. Remenyi B, Carapetis J, Wyber R, Taubert K, Mayosi BM, World Heart Federation. Position statement of the World Heart Federation on the prevention and control of rheumatic heart disease. Nat Rev Cardiol. 2013;10(5):284-92. 20. Karthikeyan G, Guilherme L. Acute rheumatic fever. Lancet. 2018; 392(10142):161-74. 21. Wyber R, Taubert K, Marko S, Kaplan EL. Benzathine penicillin G for the management of RHD: concerns about quality and access, and opportunities for intervention and improvement. Glob Heart. 2013;8(3):227-34. 22. Taubert K, Marko SB. Access to essential medicines: illuminating disparities in the global supply of benzathine penicillin G in the context of rheumatic fever/rheumatic heart disease prevention. J AmColl Cardiol. 2013;61(10):E2004. 23. Müller RE. Estudo longitudinal de pacientes portadores de cardiopatia reumatica no Rio de Janeiro. [dissertaço]. Rio Janeiro: Ministerio da Saude/ FIOCRUZ; 2008. 24. Watkins DA, Mvundura M, Nordet P, Mayosi BM. A cost-effectiveness analysis of a program to control rheumatic fever and rheumatic heart disease in Pinar del Rio, Cuba. PLoS One. 2015;10(3):e0121363. 25. Musuku J, Lungu JC, Machila E, Jones C, Colin L, Schwaninger S, et al. Epidemiology of pharyngitis as reported by Zambian school children and their families: implications for demand-side interventions to prevent rheumatic heart disease. BMC Infect Dis. 2017;17(1):473. 26. Spina GS. Febre Reumática. Título de especialista em cardiologia. 2nd ed. São Paulo: NVersos; 2014. 27. Nascimento BR, Sable C, Nunes MCP, Diamantino AC, Oliveira KKB, Oliveira CM, et al. Comparison between different strategies of rheumatic heart disease echocardiographic screening in Brazil: data from the PROVAR (Rheumatic Valve Disease Screening Program) study. J Am Heart Assoc. 2018;7(4):pii:e008039. 28. LibbyP,BonowRO,MannDL,ZipesDP,eds.Braunwald:Tratadodedoenças cardiovasculares. 10th ed. São Paulo: Elsevier; 2017. 29. Mirabel M, Bacquelin R, Tafflet M, Robillard C, Huon B, Corsenac P, et al. Screening for rheumatic heart disease: evaluation of a focused cardiac ultrasound approach. Circ Cardiovasc Imaging. 2015;8(1):pii:e002324. 30. ColquhounSM,CarapetisJR,KadoJH,SteerAC.Rheumaticheartdiseaseand its control in the Pacific. Expert Rev Cardiovasc Ther. 2009;7(12):1517-24. 31. Marijon E, Mirabel M, Celermajer DS, Jouven X. Rheumatic heart disease. Lancet. 2012;379(9819):953-64. 32. Wyber R, Zühlke L, Carapetis J. The case for global investment in rheumatic heart-disease control. Bull World Health Organ. 2014;92(10):768-70. 33. Ralph AP, Fittock M, Schultz R, Thompson D, Dowden M, Clemens T, et al. Improvement in rheumatic fever and rheumatic heart diseasemanagement andpreventionusingahealthcentre-basedcontinuousquality improvement approach. BMC Heal Serv Res. 2013 Dec 18;13:525. 34. Islam AK, Majumder AA. Rheumatic fever and rheumatic heart disease in Bangladesh: a review. Indian Heart J. 2016;68(1):88-98. 35. Watkins D, Lubinga SJ, Mayosi B, Babigumira JB. A cost-effectiveness tool to guidetheprioritizationofinterventionsforrheumaticfeverandrheumaticheart diseasecontrol inAfricanNations.PLoSNeglTropDis.2016;10(8):e0004860. 36. Watkins D, Zuhlke L, Engel M, Daniels R, Francis V, Shaboodien G, et al. Seven key actions to eradicate rheumatic heart disease in Africa: the Addis Ababa communiqué. Cardiovasc J Afr. 2016;27(3):184-7. 37. Brasil. Ministério da Saúde. Instituto Nacional do Câncer. Posicionamento do Ministério da Saúde acerca da integridadade da saúde do homem no contexto do Novembro Azul. Nota Técnica Conjunta 2015. [acesso em 08 fev 2018]. Disponível em: http://portalarquivos2.saude.gov.br/images/ pdf/2015/novembro/09/Integralidade-sa--de-homens.pdf 38. Tchou J, Wang LC, Selven B, Zhang H, Conejo-Garcia J, Borghaei H, et al. Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Cancer Res Treat. 2012;133(2):799-804. 39. Watkins DA, Roth GA. Global burden of rheumatic heart disease. N Engl J Med. 2018;378(1):e2. 40. Santos JPA, CarmoGALD , Beaton AZ, Lourenço TV, Diamantino AC, Nunes MDCP, et al. Challenges for the implementation of the first large-scale rheumatic heart disease screening program in Brazil: the PROVAR study experience. Arq Bras Cardiol. 2017;108(4):370-4. 353